LUC00078I2 - Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta - Google Patents

Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta Download PDF

Info

Publication number
LUC00078I2
LUC00078I2 LU00078C LUC00078C LUC00078I2 LU C00078 I2 LUC00078 I2 LU C00078I2 LU 00078 C LU00078 C LU 00078C LU C00078 C LUC00078 C LU C00078C LU C00078 I2 LUC00078 I2 LU C00078I2
Authority
LU
Luxembourg
Prior art keywords
treatment
mediterranean fever
familial mediterranean
beta antibodies
beta
Prior art date
Application number
LU00078C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00078(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LUC00078I2 publication Critical patent/LUC00078I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
LU00078C 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta LUC00078I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP06826560A EP1940465B1 (fr) 2005-10-26 2006-10-24 Nouvelle utilisation d' anticorps anti il-1beta
EP10181100A EP2332577A1 (fr) 2005-10-26 2006-10-24 Nouvelle utilisation de composés IL-1 béta

Publications (1)

Publication Number Publication Date
LUC00078I2 true LUC00078I2 (fr) 2018-08-14

Family

ID=37806690

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92326C LU92326I2 (fr) 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU00078C LUC00078I2 (fr) 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92326C LU92326I2 (fr) 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)

Country Status (28)

Country Link
US (9) US8105587B2 (fr)
EP (5) EP2848258B1 (fr)
JP (4) JP2009513645A (fr)
KR (3) KR101749388B1 (fr)
CN (2) CN102861332A (fr)
AU (1) AU2006306280B2 (fr)
BR (1) BRPI0617830B8 (fr)
CA (3) CA2963828A1 (fr)
CY (4) CY1113378T1 (fr)
DK (2) DK2848258T3 (fr)
ES (3) ES2944067T3 (fr)
HU (2) HUE036973T2 (fr)
IL (4) IL190545A (fr)
JO (2) JO2826B1 (fr)
LT (3) LT2848258T (fr)
LU (2) LU92326I2 (fr)
MA (1) MA29919B1 (fr)
NO (2) NO345888B1 (fr)
NZ (1) NZ567222A (fr)
PH (2) PH12013501287B1 (fr)
PL (2) PL2848258T3 (fr)
PT (2) PT2848258T (fr)
RU (2) RU2468817C2 (fr)
SI (2) SI2848258T1 (fr)
TN (1) TNSN08189A1 (fr)
TR (1) TR201802449T4 (fr)
TW (3) TWI388335B (fr)
WO (1) WO2007050607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963828A1 (fr) 2005-10-26 2007-05-03 Novartis Ag Nouvelle utilisation de composes il-1beta
AU2012203931B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
WO2008145664A1 (fr) * 2007-05-29 2008-12-04 Novartis Ag Nouvelles indications pour une thérapie anti-il-i-bêta
HRP20130042T1 (hr) * 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
TWI500427B (zh) * 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
MX2013007332A (es) * 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
CA3295783A1 (en) 2011-05-10 2026-03-02 Prometheus Laboratories, Inc. Methods of disease activity profiling for personalized therapy management
WO2017153936A1 (fr) 2016-03-10 2017-09-14 Novartis Ag Arn messager chimiquement modifié
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018234879A1 (fr) 2017-06-22 2018-12-27 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON IL-1β DANS LE TRAITEMENT DU CANCER
JP2021523894A (ja) 2018-05-09 2021-09-09 ノバルティス アーゲー カナキヌマブの使用
US20220056123A1 (en) 2018-12-21 2022-02-24 Novartis Ag Use of il-1beta binding antibodies
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
JP2022516850A (ja) 2018-12-21 2022-03-03 ノバルティス アーゲー 骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用
TWI793503B (zh) 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
KR20230109107A (ko) * 2022-01-10 2023-07-19 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
WO1995016353A1 (fr) 1993-12-14 1995-06-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Traitement systemique par genes des affections des tissus conjonctifs
WO1998002441A2 (fr) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Elements et procedes pour traiter ou prevenir les mycoses pathogènes
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU778975B2 (en) 1999-02-10 2004-12-23 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an IL-1B mutation
PT1210320E (pt) * 1999-07-16 2005-01-31 Leo Pharma As Aminobenzofenonas como inibidores de il-1beta e tnf-alfa
IL147803A0 (en) 1999-08-24 2002-08-14 Ariad Gene Therapeutics Inc 28-epirapalogs
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1282435A2 (fr) 2000-05-12 2003-02-12 Immunex Corporation Inhibiteurs d'interleukine 1 dans le traitement de maladies
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
CN1253449C (zh) 2000-11-07 2006-04-26 诺瓦提斯公司 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物
US20050075488A1 (en) * 2001-07-26 2005-04-07 Bright Stuart Willis Interleukin-1 beta antibodies
US20030049255A1 (en) 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
ATE556482T1 (de) 2001-12-01 2012-05-15 Iskra Wind Turbines Ltd Synchron-wechselstromgenerator mit einem bremsmechanismus
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
EP1478648B1 (fr) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Composes contenant du phosphore et utilisations associees
MXPA04007124A (es) 2002-02-01 2004-10-29 Omeros Corp Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago.
EP1487465A4 (fr) 2002-02-11 2007-05-30 Arkion Life Sciences Llc Facteur inhibiteur des cytokines purifie
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
JP4538461B2 (ja) * 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション，インコーポレイテッド ヒトＩＬ−１βアンタゴニスト
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2005047906A1 (fr) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
DK1720893T3 (en) 2004-02-26 2014-11-24 Baylor Res Inst COMPOSITIONS AND PROCEDURES FOR THE SYSTEMIC TREATMENT OF ARTHRITIS
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
US7459426B2 (en) * 2004-06-04 2008-12-02 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
EP1883427A4 (fr) 2005-01-20 2010-04-21 Univ Rochester Compositions et methodes permettant d'etudier et de traiter des maladies et des troubles inflammatoires
AU2006227165B2 (en) 2005-03-18 2011-11-10 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
CA2963828A1 (fr) 2005-10-26 2007-05-03 Novartis Ag Nouvelle utilisation de composes il-1beta

Also Published As

Publication number Publication date
EP2848258A1 (fr) 2015-03-18
PH12013501287A1 (en) 2016-02-01
IL245387B (en) 2019-09-26
PH12020500559A1 (en) 2021-06-14
LT2848258T (lt) 2018-02-26
KR101518064B1 (ko) 2015-05-06
ES2389110T3 (es) 2012-10-23
HK1121041A1 (en) 2009-04-17
CN101291693B (zh) 2012-10-03
IL258983B (en) 2020-10-29
IL245387A0 (en) 2016-06-30
JO2826B1 (en) 2014-09-15
MA29919B1 (fr) 2008-11-03
JP2017206552A (ja) 2017-11-24
CA2626214A1 (fr) 2007-05-03
RU2008120625A (ru) 2010-01-20
US20260125463A1 (en) 2026-05-07
EP1940465A2 (fr) 2008-07-09
PT2848258T (pt) 2018-03-20
SI2848258T1 (en) 2018-03-30
TNSN08189A1 (en) 2009-10-30
AU2006306280B2 (en) 2010-06-17
IL190545A0 (en) 2008-11-03
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
LTPA2018506I1 (lt) 2018-06-25
ES2662420T3 (es) 2018-04-06
LTC2848258I2 (lt) 2019-08-12
CY2018018I2 (el) 2018-12-12
PL2848258T3 (pl) 2018-06-29
JP6286403B2 (ja) 2018-02-28
US20170218063A1 (en) 2017-08-03
JP6061747B2 (ja) 2017-01-18
EP3332807B1 (fr) 2023-02-22
CA2898369C (fr) 2017-06-20
IL258983A (en) 2018-06-28
US20120039910A1 (en) 2012-02-16
US8409576B2 (en) 2013-04-02
CY2018018I1 (el) 2018-12-12
LU92326I2 (fr) 2014-02-05
TR201802449T4 (tr) 2018-03-21
US8105587B2 (en) 2012-01-31
CN102861332A (zh) 2013-01-09
PT1940465E (pt) 2012-10-03
BRPI0617830A2 (pt) 2011-08-09
JOP20140120B1 (ar) 2021-08-17
EP3332807A3 (fr) 2018-06-20
IL190545A (en) 2016-09-29
JP2013166757A (ja) 2013-08-29
AU2006306280A1 (en) 2007-05-03
HUS1800025I1 (hu) 2018-07-30
CA2898369A1 (fr) 2007-05-03
DK2848258T3 (en) 2018-03-19
RU2012133522A (ru) 2014-02-20
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
TWI388335B (zh) 2013-03-11
PH12013501287B1 (en) 2016-02-01
CY1113378T1 (el) 2015-11-04
NO20200810A1 (no) 2008-07-22
LU92326I9 (fr) 2019-01-16
BRPI0617830B8 (pt) 2021-05-25
US20180201674A1 (en) 2018-07-19
CN101291693A (zh) 2008-10-22
NZ567222A (en) 2011-07-29
TW200803898A (en) 2008-01-16
CY2013046I1 (el) 2015-11-04
KR20150013834A (ko) 2015-02-05
CA2626214C (fr) 2016-06-21
WO2007050607A3 (fr) 2007-06-28
EP2848258B1 (fr) 2017-12-13
US20130171167A1 (en) 2013-07-04
IL277406A (en) 2020-11-30
WO2007050607A2 (fr) 2007-05-03
DK1940465T3 (da) 2012-10-22
ES2944067T3 (es) 2023-06-19
KR101749388B1 (ko) 2017-06-20
JP2009513645A (ja) 2009-04-02
SI1940465T1 (sl) 2012-10-30
NO345888B1 (no) 2021-09-27
EP4218815A2 (fr) 2023-08-02
HK1204767A1 (en) 2015-12-04
US20080286266A1 (en) 2008-11-20
CY2013046I2 (el) 2015-11-04
TW201617097A (zh) 2016-05-16
TW201302220A (zh) 2013-01-16
EP4218815A3 (fr) 2024-03-27
EP2332577A1 (fr) 2011-06-15
US20210147533A1 (en) 2021-05-20
RU2571563C2 (ru) 2015-12-20
CA2963828A1 (fr) 2007-05-03
KR20080059598A (ko) 2008-06-30
NO20082344L (no) 2008-07-22
HUE036973T2 (hu) 2018-08-28
HK1252316A1 (en) 2019-05-24
BRPI0617830B1 (pt) 2020-10-20
CY1120018T1 (el) 2018-12-12
EP1940465B1 (fr) 2012-08-01
TWI626056B (zh) 2018-06-11
LTC1940465I2 (lt) 2017-12-11
RU2468817C2 (ru) 2012-12-10
TWI537003B (zh) 2016-06-11
US20150322148A1 (en) 2015-11-12
JP2016020377A (ja) 2016-02-04
PL1940465T3 (pl) 2013-01-31
EP3332807A2 (fr) 2018-06-13

Similar Documents

Publication Publication Date Title
LTC2848258I2 (lt) Šeiminės Viduržemio jūros karštligės gydymas su anti-IL-1 beta antikūnais
WO2007064972A3 (fr) Anticorps monoclonaux et utilisation de ceux-ci
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
IL193444A (en) Isolated reactive monoclonal antibody that binds both IL-17a and IL-17f, an isolated serum containing it, a diagnostic kit containing it, a pharmaceutical product containing it, and its use as a drug to treat or prevent inflammation or inflammatory disease.
WO2007011941A3 (fr) Anticorps neutralisants anti-b7rp1 humains
EA200870050A1 (ru) Анти-il-17-антитела
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
WO2006104989A3 (fr) Anticorps a regions fc modifiees et utilisations
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
WO2008033333A3 (fr) Variants de la famille il-1
ITMI20050562A1 (it) Dado per assemblaggio nonche' procedimento per la fabbricazione di dadi per assemblaggio
NO20076663L (no) Immunoglobuliner
WO2005070398A8 (fr) Compositions pharmaceutiques de candesartan cilexetil stabilisees par des co-solvants
WO2008100628A3 (fr) Mimétiques de la glutathione peroxydase pour le traitement de maladies neurodégénératives, pulmonaires et inflammatoires
EP2290077A3 (fr) Anticorps naturels IgM et leur inhibiteurs
WO2006109045A3 (fr) Anticorps et leurs utilisations
HK1053059A1 (zh) 新用途
WO2007058934A3 (fr) Procedes et compositions pour le traitement des troubles de la membrane basale
HK1152950A (en) Treatment of thrombocytopenia
HK1177471A (en) Anti-inflammatory antibodies and uses therefor
WO2006128911A3 (fr) Utilisation d'isoformes d'il-18bp dans le traitement et/ou la prevention de maladies inflammatoires neurologiques
WO2006090365A3 (fr) Conjugues de polysaccharide-oligoamine utiles en tant qu'agents anti-amyloides et agents antiviraux
WO2007009700A3 (fr) Utilisation de composes pyrazoliniques substitues pour le traitement de parametres des lipides du syndrome metabolique
ITFI20050231A1 (it) Scaffalatura per l'esposizione di prodotti e relativo sistema realizzativo